Ticaros
Ticaros is a South Korea-based clinical-stage biotech developing CAR-T immunotherapies using its proprietary CLIP CAR platform, with lead candidate TC011 in Phase 2 for blood cancers and TC091 entering Phase 1 for solid tumors. The company is pre-revenue and serves relapsed/refractory hematologic cancer patients.
- Company typePrivate
- Founded2008
- HeadquartersSeongdong, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
Ticaros firmographics
Firmographics- Name
- Ticaros
- Legal name
- Ticaros
- Website
- https://ticaros.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ticaros is a South Korea-based clinical-stage biotech developing CAR-T immunotherapies using its proprietary CLIP CAR platform, with lead candidate TC011 in Phase 2 for blood cancers and TC091 entering Phase 1 for solid tumors. The company is pre-revenue and serves relapsed/refractory hematologic cancer patients.
- Ownership category
- akta.pro rank
Ticaros industry classification
Industry- Product category
- CAR-T Cell Therapy / Cancer Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
Keywords
Where Ticaros is headquartered
LocationHeadquarters
- HQ city
- Seongdong
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Ticaros business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CAR-T Therapy Commercialization: Pre-revenue biotech company developing CAR-T immunotherapies for blood cancers and solid tumors. TC011 for blood cancer (B-cell lymphoma, follicular lymphoma) and TC091 for solid tumors are in clinical trials. Revenue will come from commercializing these therapies upon regulatory approval.
Distribution channels1 record
Marketing channels2 records
Ticaros product offering
Product offeringCore offering
Ticaros is a South Korea-based biotech company developing CAR-T immunotherapy drug candidates for cancer treatment, built on its proprietary CLIP CAR platform. Its lead candidate TC011 targets blood cancers (relapsed/refractory B-cell lymphoma and follicular lymphoma) and is in Phase 2 trials after Phase 1 showed 100% objective response rate and 100% complete remission in nine evaluable patients with no neurotoxicity. TC091 is its solid-tumor CAR-T candidate advancing into Phase 1 clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- TC011 CAR-T cell therapy candidate for the treatment of relapsed or refractory B-cell lymphoma and follicular lymphoma; currently in Phase 2 clinical development after demonstrating 100% ORR and 100% CR with no neurotoxicity in Phase 1.
- TC091 CAR-T cell therapy candidate for solid tumors, built on Ticaros' proprietary CLIP CAR platform; advancing into Phase 1 clinical trials, with CDMO manufacturing partnership with Matica Biolabs (CHA Biotech subsidiary) for clinical supply.
Quantifiable outcome
- 100% objective response rate and 100% complete remission in 9 eligible patients with relapsed or refractory B-cell lymphoma
- +1 more outcomes
Companies that use Ticaros
Customer profileSegments1 record
Ideal customer profiles1 record
Ticaros technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Ticaros partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Matica Biolabs (CHA Biotech subsidiary)coreCDMO agreement for production of clinical trial material for solid tumor CAR-T candidate TC091. Matica Biolabs plans to use this project to expand further into solid tumor cell therapies. This is a manufacturing partnership for clinical supply.
- Korea Drug Development FundcoreTC091 was selected as a Korea Drug Development Fund project, providing funding and recognition for the drug development program.
- Ministry of Food and Drug SafetycoreTC091 received designation under the Ministry of Food and Drug Safety's Bio Challenger program, a regulatory support initiative for innovative biotech projects.
Scale indicators3 records
Ticaros competitors and assessment
Company assessmentDirect peers
- CARSgen Therapeutics: China-based clinical-stage CAR-T developer with multiple autologous CAR-T candidates in hematologic and solid tumor indications. Directly comparable to Ticaros in technology platform (CAR-T), clinical stage, and Asia-based biotech profile.
- JW Therapeutics: Hong Kong/China-based cell therapy company focused on CAR-T therapies for hematologic malignancies, with approved product Carteyva. Comparable as an Asia-based CAR-T company navigating clinical-stage development toward commercialization.
- Allogene Therapeutics: US-based allogeneic CAR-T developer with clinical programs in both hematologic and solid tumor indications. Comparable technology category (engineered T-cell therapies) and clinical-stage profile targeting similar indications.
- Autolus Therapeutics: UK-based clinical-stage CAR-T company with lead hematology program and pipeline of next-generation cell therapies. Comparable as a clinical-stage CAR-T developer targeting B-cell malignancies with engineered T-cell platforms.
- Poseida Therapeutics: US-based clinical-stage cell therapy company developing CAR-T candidates for hematologic malignancies and solid tumors using proprietary platforms. Comparable technology approach (engineered CAR-T) and clinical stage profile.
- Adaptimmune Therapeutics: UK/US-based clinical-stage cell therapy company developing engineered T-cell therapies (TCR-T) for solid tumors. Comparable as a clinical-stage engineered T-cell therapy developer focused on solid tumor indications like Ticaros' TC091.
- Cellectis: France-based clinical-stage gene-editing and CAR-T company with allogeneic CAR-T pipeline. Comparable technology category (engineered T-cell therapies) and clinical-stage development of CAR-T candidates.
- Legend Biotech: China/US-based cell therapy company with approved BCMA-directed CAR-T (Carvykti) for multiple myeloma, developed in partnership with J&J. Comparable as a CAR-T developer that progressed from clinical stage to approval, providing a relevant benchmark for Ticaros' potential trajectory.
Broad incumbents
- Gilead Sciences (Kite Pharma): Global pharma with leading CAR-T franchise (Yescarta, Tecartus) through Kite Pharma subsidiary, dominating CD19 CAR-T in B-cell lymphomas. Comparable as the dominant commercial CAR-T player in Ticaros' target indication, representing both the competitive set and a potential strategic acquirer.
- Bristol Myers Squibb (Celgene/Juno): Global pharma with multiple CAR-T products (Breyanzi, Abecma) through Celgene/Juno acquisition, leading in CD19 and BCMA CAR-T. Comparable as an established CAR-T incumbent in Ticaros' target indications and a likely strategic acquirer or partner.
Market position
Customer concentration
Ticaros financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ticaros leadership team
Management profileNumber of profiles
Ticaros funding detail
Funding detailFunding overview
Funding rounds3 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ticaros M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ticaros
What does Ticaros do?
Ticaros is a South Korea-based biotech company developing CAR-T immunotherapy drug candidates for cancer treatment, built on its proprietary CLIP CAR platform. Its lead candidate TC011 targets blood cancers (relapsed/refractory B-cell lymphoma and follicular lymphoma) and is in Phase 2 trials after Phase 1 showed 100% objective response rate and 100% complete remission in nine evaluable patients with no neurotoxicity. TC091 is its solid-tumor CAR-T candidate advancing into Phase 1 clinical trials.
Is Ticaros a public or private company?
Ticaros is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ticaros founded?
Ticaros was founded in 2008. It employs 11 to 50 people.
Where is Ticaros based?
Ticaros is headquartered in Seongdong, South Korea, in the Asia region.
How does Ticaros make money?
One revenue line is on record: CAR-T Therapy Commercialization.
Who are Ticaros's main competitors?
Direct peers on record are CARSgen Therapeutics, JW Therapeutics, Allogene Therapeutics, Autolus Therapeutics, Poseida Therapeutics, Adaptimmune Therapeutics, Cellectis and Legend Biotech. Broad incumbents are Gilead Sciences (Kite Pharma) and Bristol Myers Squibb (Celgene/Juno).
Does Ticaros have an API?
No public API is recorded for Ticaros.
What industry is Ticaros in?
Ticaros's product category is CAR-T Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 541714 and its SIC code is 2836.